While no negative side effects were reported on IFN-α therapies of cancer, experimental data suggested that interferon signaling via toll-like receptor 7 prevented cholestasis and hepatotoxin-induced liver fibrosis in a rodent model (125). Here, IFNA17 is linked to cancer.